Tag: Novo Nordisk

Novo Nordisk sets up a GMP manufacturing facility in USA

novo nordisk
Novo Nordisk announced the establishment of a manufacturing site in Fremont, California (USA) to develop and produce stem cell-based therapies.

Novo Nordisk announced the global launch of connected insulin pens

novo-nordisk
Novo Nordisk announced plans to make the durable, connected insulin pens NovoPen® 6 and NovoPen Echo® Plus commercially available across key markets commencing in early 2019.

Novo Nordisk insulin full cycle production launched in Kaluga

novo-nordisk kaluga
An official ceremony dedicated to the launch of Novo Nordisk insulin full cycle production was held on September 19, 2018 in Grabtsevo Industrial Park, Kaluga Region.

Novo Nordisk intends to restructure its R&D organization

novo nordisk
Novo Nordisk announced plans to restructure its Research & Development (R&D) organisation to accelerate the expansion and diversification of its pipeline across serious chronic diseases.

Novo Nordisk opens a new research centre in Oxford

novo-nordisk
A new centre for research to develop a new generation of medicines that will transform the lives of people living with diabetes opened in Oxford (UK).

Novo Nordisk entered into a research collaboration with Ossianix

novo nordisk
Novo Nordisk signed a research collaboration and option agreement with Ossianix to deliver therapeutic molecules in diabetes and other metabolic diseases across the Blood Brain Barrier to the brain.

Evotec sets up alliance with Novo Nordisk to develop novel diabetes therapies

diabetes
Evotec AG announced a strategic alliance with Novo Nordisk to discover and develop novel small molecule therapies to treat patients suffering from diabetes and obesity.

Novo Nordisk acquired British specialist chemistry company Ziylo

novo nordisk
Ziylo and Novo Nordisk announced that Novo Nordisk has acquired all of the shares of Ziylo, a University of Bristol spin-out company based at Unit DX science incubator in Bristol, UK.

Novo Nordisk Pharmatech signs a distribution agreement with Signet

Novo Nordisk
Novo Nordisk Pharmatech has entered into an agreement with Signet Chemical for the distribution of their pharmaceutical range of quaternary ammonium compounds in India, Bangladesh and Sri Lanka.

Kallyope enters into drug discovery collaboration with Novo Nordisk

drug discovery
Kallyope Inc. and Novo Nordisk entered into a research collaboration and option agreement to discover novel peptide therapeutics to treat obesity and diabetes.

Epigen Biosciences licenses kidney disease medicine to Novo Nordisk

chemistry
Epigen Biosciences entered into a collaboration agreement with Novo Nordisk A/S under which Novo Nordisk has licensed the LPA1 receptor antagonist EPGN696 for development in diabetic and chronic kidney disease.

Novo Nordisk increases its ambition for stem cell-based therapies

Novo Nordisk
Novo Nordisk has licenced a technology to enable the generation of good manufacturing practice compliant human embryonic stem cell lines as well as the rights to further develop these into future regenerative medicine therapies.

Novo Nordisk will launch a new shop for insulin production in Russia

novo-nordisk
Novo Nordisk, a Danish pharmaceutical company, will launch a production facility for full-cycle manufacturing of insulin in Kaluga region. Novo Nordisk insulin plant was commissioned in the Kaluga region in 2015.

Novo Nordisk received licence for sickle cell disease drug from EpiDestiny

novo nordisk
Novo Nordisk and EpiDestiny today announced that Novo Nordisk has obtained an exclusive worldwide licence to EpiDestiny's sickle cell disease (SCD) programme, EPI01.

Ibnsina Pharma will distribute Novo Nordisk products in Egypt

ibnsina pharma egypt
Ibnsina Pharma, Egypt’s fastest-growing and second-largest pharmaceutical distributor, has signed two contracts with Novo Nordiskto distribute over 20 stock-keeping units of its products in Egypt.

Novo Nordisk obesity drug showed promising results during clinical trial

novo nordisk
Semaglutide, developed by Novo Nordisk, is an analogue of the human glucagon-like peptide (GLP-1) hormone, and induces weight loss by reducing hunger, increasing feelings of fullness and helping people eat less.